The experimental drug that could stop melanoma in its tracks



Related Articles

Melanoma may not be the most common type of skin cancer, but it causes the most deaths, with an estimated 10,130 people in the United States succumbing to it annually, according to the Skin Cancer Foundation. Called melanoma because it develops in the cells that produce melanin, this cancer is almost always curable when caught and treated early. If missed, however, it can metastasize and become very difficult to treat. The Skin Cancer Foundation estimates that this year, 76,380 of all melanoma cases will be invasive, with about 46,870 in males and 29,510 in women.

But now hope may be delivered via an experimental cancer drug that is showing significant promise for stopping melanoma, and possibly other forms of cancer, in its tracks. It may even be effective against melanomas that have resisted other forms of treatment.

The drug — called pevonedistat — is already being tested in people. Until now, scientists have been unable to determine exactly how it kills cancer cells, but they have confirmed that the drug shuts down hundreds, if not thousands, of different cellular proteins. Researchers from the University of Virginia School of Medicine (UVA), led by Tarek Abbas, PhD, of the Department of Radiation Oncology and the UVA Cancer Center, have determined that the drug acts on a particular protein that melanomas and other cancers rely on to replicate with great speed and deadly effect. By denying the cancers this essential ingredient, doctors may be able to halt melanomas and other forms of the disease.

University of Virginia School of Medicine researchers (from left) Kangping Du, Ph.D.; graduate student Mouadh Benamar; and Tarek Abbas, Ph.D. Photo courtesy of Josh Barney | UVA Health System.

"We think that this is what lets the cancer cells cope with the amount of replication they must undergo," Abbas said. "They divide in uncontrolled fashion, and those cells that divide faster and more frequently are under tremendous replication stress, so these cancer cells needed to be able to develop a way to cope with that."

The critical protein blocked by pevonedistat is produced by the gene CDT2, and it is vital for malignant cancer cells to survive. Without it, the cells stop replicating and begin to fall apart. "We have great understanding now for how the drug works," Abbas said. "And we think the drug works not because of its intended target, but rather because it works on [the CDT2 protein] way downstream of that."

Excessive amounts of the protein are produced in melanoma cells, and patients with high levels of it are less likely to survive. "These tumors, and not necessarily just melanoma, they are addicted to this gene," Abbas said. "And that makes them very susceptible to the drug. In fact, we showed that melanoma cells that have higher levels of expression of CDT2 are much more susceptible to the drug."

High levels of the CDT2 protein are also found in many other tumors, he noted, including brain, breast and liver tumors. Doctors may one day use the level of the protein as a way to gauge disease prognosis.

The safety and effectiveness of pevonedistat in people is still being tested, and it is not yet available as a treatment. But Abbas, who has not been involved in the drug's testing, is optimistic based on his findings. "We have great hope that this drug will have very significant impact on melanoma in general. In fact, the drug is very effective on all melanomas, including those for which an effective therapeutic is lacking," he said. "We actually show this drug can work on melanoma that resisted treatment, which is a major challenge in melanoma therapy. If approved by the FDA and it moves forward, this drug could potentially be a good second-line therapy for those patients that fail initial treatment."

The findings have been published online by the scientific journal EBioMedicine. The research team consisted of Mouadh Benamar, Fadila Guessous, Kangping Du, Patrick Corbett, Joseph Obeid, Daniel Gioeli, Craig L. Slingluff Jr. and Abbas.